Drug Trial Radar · NCT06335303
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
322
Actual
Start
Sep 5, 2024
Primary completion
Nov 25, 2025
Study completion Jan 16, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study. Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff. At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
BI 1819479Drug
BI 1819479
Placebo matching BI 1819479Drug
Placebo matching BI 1819479
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year]Time frame: Up to 52 weeks
Locations
163 sites in 28 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Critical Care, Pulmonary and Sleep Associates
Lakewood, Colorado
Clinical Research Specialists LLC - Kissimmee
Kissimmee, Florida
SEC Clinical Research
Pensacola, Florida
The Iowa Clinic, PC
West Des Moines, Iowa
Advanced Pulmonary Research
Warren, Michigan
Memorial Hospital Gulfport
Gulfport, Mississippi
Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine
New Bern, North Carolina
Southeastern Research Center-Winston Salem-69289
Winston-Salem, North Carolina
Clinical Research Associates of Central PA
DuBois, Pennsylvania
Temple University
Philadelphia, Pennsylvania
Lowcountry Lung and Critical Care
Charleston, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina
Clinical Trials Center of Middle Tennessee, LLC
Franklin, Tennessee
Pulmonary Associates of Richmond, Inc.
Richmond, Virginia
Centro de Investigaciones Metabolicas (CINME)
C.a.b.a, Argentina
Hospital Britanico de Buenos Aires
CABA, Argentina
Centro de Investigación Clinica Belgrano
CABA, Argentina
CEDIC - Centro de Investigacion Clinica
CABA, Argentina
Consultorios Médicos del Buen Ayre
Capital Federal, Argentina
Macquarie University
Macquarie Park, Australia
Canberra Hospital
Garran, Australian Capital Territory, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Launceston Respiratory & Sleep Centre
Launceston, Tasmania, Australia
Lung Research Victoria
Footscray, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
Medical University of Graz
Graz, Austria
Krems University Hospital
Krems, Austria
Johannes Kepler University Linz
Linz, Austria
Hospital Elisabethinen Linz
Linz, Austria
Standort Penzing der Klinik Ottakring
Vienna, Austria
Clinic Floridsdorf
Vienna, Austria
Klinikum Wels - Grieskirchen GmbH
Wels, Austria
Cliniques Universitaires Saint-Luc
Brussels, Belgium
CHR de la Citadelle
Liège, Belgium
Serviços Medicos Respirar Sul Fluminense
Barra Mansa, Brazil
Faculdade de Medicina de Botucatu - UNESP
Botucatu, Brazil
Hospital das Clínicas da UFG - EBSERH
Goiânia, Brazil
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.